Agnese C. Latorre

Bari, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Case Report: A successful multidisciplinary approach to doxorubicin extravasation from a PICC-port in a patient with breast cancer.

Case Report: A successful multidisciplinary approach to doxorubicin extravasation from a PICC-port in a patient with breast cancer.

Journal: Frontiers in oncology
Published: November 25, 2024

Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model.

Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model.

Journal: Cancer medicine
Published: July 01, 2024

DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study.

DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study.

Journal: Cancers
Published: June 26, 2024

Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.

Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.

Journal: Future oncology (London, England)
Published: June 12, 2024

Prediction of breast cancer Invasive Disease Events using transfer learning on clinical data as image-form.

Prediction of breast cancer Invasive Disease Events using transfer learning on clinical data as image-form.

Journal: PloS one
Published: January 17, 2024

Explainable 3D CNN based on baseline breast DCE-MRI to give an early prediction of pathological complete response to neoadjuvant chemotherapy.

Explainable 3D CNN based on baseline breast DCE-MRI to give an early prediction of pathological complete response to neoadjuvant chemotherapy.

Journal: Computers in biology and medicine
Published: June 28, 2023

Analyzing breast cancer invasive disease event classification through explainable artificial intelligence.

Analyzing breast cancer invasive disease event classification through explainable artificial intelligence.

Journal: Frontiers in medicine
Published: December 05, 2022

Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer.

Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer.

Journal: Scientific reports
Published: November 04, 2022

Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients: A machine learning approach.

Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients: A machine learning approach.

Journal: Cancer medicine
Published: October 17, 2022

A machine learning ensemble approach for 5- and 10-year breast cancer invasive disease event classification.

A machine learning ensemble approach for 5- and 10-year breast cancer invasive disease event classification.

Journal: PloS one
Published: June 09, 2022

Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer.

Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer.

Journal: Expert opinion on investigational drugs
Published: May 16, 2022

Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes.

Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: April 01, 2022
Showing 1-12 of 32

Last Updated: 09/26/2026